Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

C-terminus of p53 is required for G2 arrest

Abstract

Mutation of four lysine residues in the p53 C-terminal domain inhibits MDM2-dependent ubiquitination of p53 and alters its subcellular distribution. This implies that modification (such as acetylation and phosphorylation) of amino acid residues in p53 C-terminal domain, regulate the biological functions of p53. In this study, we demonstrated that p53 with lysine residues 372, 373, 381, and 382 mutated to alanine (the A4 mutant) retained the transactivation activity of wild-type p53, although the transactivation activity of p21 promoter by the A4 mutant was slightly reduced. The inducible expression of wild-type p53 and the A4 mutant in H1299 cells caused growth inhibition due to cell-cycle arrest. Consistent with previous studies, the expression of wild-type p53 elicited G1 and G2 arrests. However, the cells expressing the A4 mutant underwent G1 arrest but not G2 arrest. Cyclin B1-associated kinase activity was reduced in cells expressing wild-type p53 but not A4, when the cells underwent G2 arrest. This suggests that modification of the p53 C-terminal domain might inhibit p53-mediated G2 arrest. In other words, p53 requires an intact C-terminus to induce G2 arrest.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Agarwal ML, Agarwal A, Taylor WR, Stark GR . 1995 Proc. Natl. Acad. Sci. USA 92: 8493–8497

  • Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD . 1999 Proc. Natl. Acad. Sci. USA 96: 13777–13782

  • Chen X, Ko LJ, Jayaraman L, Prives C . 1996 Genes Dev. 10: 2438–2451

  • Cox LS, Lane DP . 1995 BioEssays 17: 501–508

  • Gottlieb TM, Oren M . 1996 Biochim. Biophys. Acta 1287: 77–102

  • Gu W, Roeder RG . 1997 Cell 90: 595–606

  • Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ . 1993 Cell 75: 805–816

  • Hartwell LH, Weinert TA . 1989 Science 246: 629–634

  • Haupt Y, Barak Y, Oren M . 1996 EMBO J. 15: 1596–1606

  • Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B . 1997 Mol. Cell 1: 3–11

  • Hunter T, Pines J . 1994 Cell 79: 573–582

  • Innocente SA, Abrahamson JL, Cogswell JP, Lee JM . 1999 Proc. Natl. Acad. Sci. USA 96: 2147–2152

  • Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, Yao TP . 2001 EMBO J. 20: 1331–1340

  • Kagawa S, Fujiwara T, Hizuta A, Yasuda T, Zhang WW, Roth JA, Tanaka N . 1997 Oncogene 15: 1903–1909

  • King RW, Jackson PK, Kirschner MW . 1994 Cell 79: 563–571

  • Ko LJ, Prives P . 1996 Genes Dev. 10: 1054–1072

  • Levine AJ . 1997 Cell 88: 323–331

  • Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD, Berger SL . 1999 Mol. Cell. Biol. 19: 1202–1209

  • Lopez-Girona A, Furnari B, Mondesert O, Russell P . 1999 Nature 397: 172–175

  • Nakamura S, Roth JA, Mukhopadhyay T . 2000 Mol. Cell. Biol. 20: 9391–9398

  • Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y . 2000 Cell 102: 849–862

  • Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E . 1998 Genes Dev. 12: 2831–2841

  • Shieh SY, Ikeda M, Taya Y, Prives C . 1997 Cell 91: 325–334

  • Shieh SY, Taya Y, Prives C . 1999 EMBO J. 18: 1815–1823

  • Stewart N, Hicks GG, Paraskevas F, Mowat M . 1995 Oncogene 10: 109–115

  • Taylor WR, DePrimo SE, Agarwal A, Agarwal ML, Schonthal AH, Katula KS, Stark GR . 1999 Mol. Cell. Biol. 10: 3607–3622

  • Unger T, Juven-Gershon T, Moallem E, Berger M, Vogt SR, Lozano G, Oren M, Haupt Y . 1999 EMBO J. 18: 1805–1814

  • Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, Yu L, Hollander MC, O'Connor PM, Fornace AJJ, Harris CC . 1999 Proc. Natl. Acad. Sci. USA 96: 3706–3711

  • Wang Y, Blandino G, Oren M, Givol D . 1998 Oncogene 17: 1923–1930

  • Yun J, Chae HD, Choy HE, Chung J, Yoo HS, Han MH, Shin DY . 1999 J. Biol. Chem. 274: 29677–29682

  • Zhan Q, Antinore MJ, Wang XW, Carrier F, Smith ML, Harris CC, Fornace Jr AJ . 1999 Oncogene 18: 2892–2900

Download references

Acknowledgements

We thank Marjorie Johnson for her technical assistance, Maureen Goode, PhD (Scientific Publications Dept.) for editing assistance, and Carmelita Concepcion and Peggy James for preparation of this manuscript. This work was partially supported by grants from the National Cancer Institute and the National Institutes of Health (P01 CA78778-01A1) [JA Roth]; SPORE (2P50-CA70970-04); a developmental grant from the NCI for the University of Texas M. D. Anderson Cancer Center SPORE (P50-CA70907) in lung cancer (T Mukhopadhyay); by gifts to the Division of Surgery from Tenneco and Exxon for the Core Laboratory Facility; by the UT M. D. Anderson Cancer Center Support Core Grant (CA 16672); by a grant from the Tobacco Settlement Funds as appropriated by the Texas State Legislature (Project 8); the W. M. Keck Foundation; and a sponsored research agreement with Introgen Therapeutics, Inc. (SR93-004-1).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Tapas Mukhopadhyay.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakamura, S., Gomyo, Y., Roth, J. et al. C-terminus of p53 is required for G2 arrest. Oncogene 21, 2102–2107 (2002). https://doi.org/10.1038/sj.onc.1205251

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205251

Keywords

This article is cited by

Search

Quick links